Response Rates and Survival Outcomes for Ponatinib Among Patients Who Failed Second-generation Tyrosine Kinase Inhibitors

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the response rates and survival outcomes were for ponatinib among patients who failed second-generation tyrosine kinase inhibitors in the OPTIC trial.

Pharmacy Times® interviewed Hagop Kantarjian, MD, the professor and chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, on one of his presentations at the 62nd ASH Annual Meeting and Exposition. The presentation looks at the efficacy and safety of ponatinib in patients with chronic-phase chronic myeloid leukemia who failed one or more second-generation tyrosine kinase inhibitors.

In this video, Kantarjian discusses what the response rates and survival outcomes were for ponatinib among patients who failed second-generation tyrosine kinase inhibitors in the OPTIC trial, whether the efficacy outcomes in the OPTIC trial were consistent with that of the PACE trial, and what this means for the response-adjusted dosing regimen of ponatinib.